Cocrystal Pharma has begun a Phase Ia/Ib clinical trial of CC-31244, a pan-genotypic, potent NS5B non-nucleoside inhibitor (NNI), to treat chronic hepatitis C virus (HCV) infection.

Hepatitis C is a viral infection of the liver and as per the World Health Organisation estimate, in 2013 the disease affected more than 150 million people worldwide.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Most patients develop chronic infections that can lead to fibrosis (scarring), cirrhosis, liver failure, and liver cancer.

The Phase Ia/Ib clinical trial of CC-31244 is currently enrolling subjects and has already dosed the first subject with no serious adverse events reported.

"Based on the drug’s preclinical safety profile, drug resistance profile and low nanomolar in vitro potency, the goal is to determine the antiviral activity and safety of CC-31244 in humans."

The company noted that the multi-centre, double-blind, randomised, placebo-controlled single ascending oral dose and multiple oral dose trial is designed to evaluate CC-31244’s safety / tolerability, pharmacokinetics including food effect and antiviral activity in up to 88 subjects.

See Also:

The trial will involve two groups, A and B. Group A covers single ascending doses, and multiple doses in healthy volunteers, while group B includes multiple doses in HCV infected individuals.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The dosing of Group B will be conducted after the safety and pharmacokinetic review of Group A.

Cocrystal Pharma chief medical officer Douglas Mayers said: "Based on the drug’s preclinical safety profile, drug resistance profile and low nanomolar in vitro potency, the goal is to determine the antiviral activity and safety of CC-31244 in humans."

The company expects to use CC-31244, which has been developed using its structure-based drug design technology, in an all oral, ultra-short HCV combination therapy.